All content published for the Inner Circle members
🟦 Introduction Pepsi just reported better than expected earnings and saw its stock pop 6% on the news. It now also forecasts smaller annual earnings decline than previously forecasted. This comes after a period of declining sales and earnings in response to the launch of GLP-1 as well as the impact of the new focus […]
The first half of the year is done and dusted. The markets have been all over the place, but all our portfolios have performed extremely well. We have not only beat the S&P 500 in 3 out of 4 portfolios (and were in line with the market in the 4th portfolio), but our flagship Small
AIC Portfolios – Outperforming the Market in First Half Read More »
We continue with our review of the company I consider the next Berkshire Hathaway. In this 3rd and final post, I look at the component businesses and arrive at a sum of the parts valuation for the company. As a result, I find that the stock today is selling at 39% discount to the fair
[Inner Circle] The Next Berkshire Hathaway, Part 3, Final Read More »
Previously I introduced the company I am positing as the next Berkshire Hathaway. This is a call I do not make lightly, and therefore, the research is deeper and more extensive. After all, we are looking at something we might hold for decades. If you have not read the Part 1, you can do so
[Inner Circle] The Next Berkshire Hathaway – Part 2, The Financials Read More »
It takes a special kind of company to be crowned the Next Berkshire Hathaway, and I believe I have found one. Warren Buffett invested in this company and sat on its Board for 37 years. Tom Gayner from Markel is a current Director. The management of the company is disciplined and plays for the long
[Inner Circle] The Next Berkshire Hathaway – Part 1 Read More »
[This article was originally published on Apr 27, 2025] Martin Shkreli, the poster boy for pharma greed, criticized this company at the rate it was raising its prices for EpiPen. On 2009 the wholesale price of two EpiPens was about $100, by July 2013 the price was about $265, in May 2015 it was around
[Inner Circle] $VTRS – Viatris, a Low Hanging Fruit in the Pharmaceutical Industry Read More »
[This analysis was originally published on March 20, 2025] You can build an industrial behemoth with a single idea. This is what this company did. They started out building interchangeable handles and sockets for the automotive repair industry in 1920. Automobiles were just catching on and repair was a growing market. Pretty soon, they started
[Inner Circle] $SNA – Dividend Fortress Portfolio Stock Review Read More »
[This report was originally published on March 2, 2025] 20% of the stock of this small cap company has been shorted. A whole lot of investors expect the company to fail. The stock price has declined 31% in the last 1 year. For a contrarian, this may be enough to take a position against the
[Inner Circle] $SCVL – Small Cap Value with Growth Characteristics Read More »
[This article was originally posted on January 29, 2025] Bank of America Sees Market Bottoming for This Chemical Giant in 2025 Bank of America upgraded this stock from Underperform to Buy on January 14, 2025. That’s a major shift—how often do you see analysts leapfrogging multiple rating levels in one go? Why the Sudden Upgrade? Let’s Look at the Facts
[This article was originally published on Dec 8, 2024] At first glance, you see nothing more than a mediocre company struggling to make a profit and in search of direction. Run any of the typical value screens based on earnings or profits, and you will immediately discard this stock from your watchlist. Indeed, many investors
